ADAMTS13 in pediatric sepsis: a prognostic biomarker with potential therapeutic implications

Background Growing evidence implicates a pro-thrombotic state, caused by ADAMTS13 deficiency, in sepsis-associated organ dysfunction, but pediatric data is limited. Our purpose was to evaluate association of ADAMTS13 with prognosis of pediatric sepsis. Results This was prospective observational stud...

Full description

Saved in:
Bibliographic Details
Published in:The Gazette of the Egyptian Paediatric Association 2023-12, Vol.71 (1), p.71-11, Article 71
Main Authors: El-Mekkawy, Muhammad Said, El-Deeb, Sara Mahmoud, El-Hanafy, Maha Fawzy
Format: Article
Language:English
Subjects:
A disintegrin-like and metalloprotease with thrombospondin type 1 motif, 13
ADAMTS13
Blood platelets
Creatinine
Glycoproteins
Health aspects
Infection
Intensive care
Laboratories
Medical prognosis
Medicine
Medicine & Public Health
Mortality
Multiple organ dysfunction syndrome
Pediatric
Pediatric intensive care
Pediatrics
Prognosis
Regression analysis
Risk factors
Sepsis
Septic shock
Survival analysis
Taiwan
Thrombocytopenia
Thrombosis
Variables
Ventilators
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Growing evidence implicates a pro-thrombotic state, caused by ADAMTS13 deficiency, in sepsis-associated organ dysfunction, but pediatric data is limited. Our purpose was to evaluate association of ADAMTS13 with prognosis of pediatric sepsis. Results This was prospective observational study, conducted on 70 children with sepsis and 18 healthy controls. Patients were classified upon Pediatric Intensive Care Unit (PICU) admission into sepsis, severe sepsis, and septic shock groups. Serum ADAMTS13 was measured within 24 h of admission. The primary outcome was all-cause PICU mortality. ADAMTS13 was lower among patients than controls [median and interquartile range (IQR): 1.30 (0.88–3.13ng/mL ) vs. 6.00 (5.55–6.50 ng/mL ); p  
ISSN:2090-9942
1110-6638
2090-9942
DOI:10.1186/s43054-023-00219-1